LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Is Lowering NovoCure (NVCR) Q3 24 Estimate To -0.41 From -0.38 5/2/2024 1:39:23 PM
  • Wedbush Is Lowering NovoCure (NVCR) Q2 24 Estimate To -0.43 From -0.37 5/2/2024 1:39:07 PM
  • Wedbush Reiterates NovoCure (NVCR) At Neutral With $21 Price Target 5/2/2024 1:37:29 PM
  • Wedbush Reiterates NovoCure (NVCR) At Neutral With $21 Price Target 3/27/2024 9:47:52 PM
  • Zai Lab : Novocure's METIS Phase 3 Trial Achieves Primary Endpoint In Brain Metastases Treatment 3/27/2024 9:35:24 AM
  • Wedbush Reiterates NovoCure (NVCR) At Neutral With $21 Price Target 1/8/2024 4:37:55 PM
  • Wedbush Is Cutting NovoCure (NVCR) FY20 Rev. Estimate To 484.6 M From 1601 M 7/26/2019 8:36:26 AM
  • Wedbush Is Lowering NovoCure (NVCR) Q4 20 Rev. Estimate To 132.8 M From 1163 M 7/26/2019 8:36:01 AM
  • Wedbush Is Lowering NovoCure (NVCR) Q3 20 Rev. Estimate To 124.8 M From 866.4 M 7/26/2019 8:35:49 AM
  • Wedbush Is Cutting NovoCure (NVCR) Q2 20 Rev. Estimate To 118.8 M From 609.0 M 7/26/2019 8:35:24 AM
  • Wedbush Is Lowering NovoCure (NVCR) Q1 20 Rev. Estimate To 108.2 M From 492.1 M 7/26/2019 8:35:11 AM
  • Wedbush Is Increasing NovoCure (NVCR) FY19 Rev. Estimate To 351.1 M From 348.3 M 7/26/2019 8:34:51 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap